Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: A post hoc analysis from a Phase III trial
Front Pharmacol 2025;16:1683508 Doi: 10.3389/fphar.2025.1683508
Lui et al. showed that Ivarmacitinib significantly reduces the need for adding or escalating medications compared to PBO, thereby potentially decreasing treatment burden. Authors evaluated ivarmacitinib in patients with moderate-to-severe active RA who had IR to csDMARDs.
Ivarmacitinib reduced the need for adding or escalating medications particularly oral GCs and NSAIDs in patients with moderate-to-severe RA. Switching from PBO to ivarmacitinib also provides notable effects on reducing the needs of adding or escalating medications in patients with RA. However, the post hoc, exploratory nature of this study requires further validation for the findings.
